DOCSLIB.ORG

Constipation Part 2: Implications for Palliative Care

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Constipation Part 2: Implications for Palliative Care Evidence About the Pharmacological Management of CONSTIPATION PART 2: IMPLICATIONS FOR PALLIATIVE CARE Constipation remains a challenging problem for patients and caregivers in home healthcare. Part 1 of this two-part series discussed the scope, physiology, and evidence-based prac- tice for nonpharmacological interventions for constipation. This second article will focus on evidence-based pharmacological prevention and management of constipation, medication cost, and implications for palliative care. Matthew Pitlick, PharmD, BCPS, and Deborah Fritz, PhD, RN vol. 31 • no. 4 • April 2013 Home Healthcare Nurse 207 Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. While eliminating causative factors and increasing fluid/fiber intake should be attempted when possible, these are often inappropriate or unreasonable options in palliative care. Many medications are available and differ in efficacy, safety, adverse effect profile, overall tolerability, and cost. Case Study Introduction focuses on pharmacologic treatment of constipa- Mr. M. is a 66-year-old African American man who tion and implications for palliative care patients. was diagnosed with multiple myeloma 3 months ago after complaints of bone pain and fatigue. His Pharmacological Therapy problem list includes anemia, hypercalcemia, Bulk-Forming Laxatives and well-controlled diabetes mellitus on oral These agents’ bulk-forming laxatives, including medications. He is receiving lenalidomide, dexa- methylcellulose, polycarbophil, and psyllium, bulk methasone, and melphalan to treat his cancer. He stool contents, increase retention of water, and in- is not eligible for an autologous stem cell trans- crease the rate of stool transit through the intes- plantation. Ms. M. states that her husband has tine (Powell & Fleming, 2011). These actions result less energy to do the activities he has enjoyed in increased stool frequency. Bulk-forming laxa- since retirement. Although his bone pain is now tives may take 3 to 5 days for effect but can take well controlled, she is concerned that his chronic longer. Adequate fluid intake (1.5–2 L) is required constipation is affecting his quality of life. for use. Abdominal distention and flatulence are Mr. M.’s current medications are: common adverse effects but can resolve with contin- ued use. In general, these laxatives should not be • lenalidomide orally 25 mg daily, used in palliative care situations, as they can cause • dexamethasone orally 40 mg in the morning, obstructions of the esophagus, stomach, small intes- • melphalan orally 6 mg daily, tine, and colon, especially with inadequate fluid • zoledronic acid 4 mg IV every 4 weeks, intake (Powell & Fleming, 2011; Spinzi et al., 2009). • metformin orally 1,000 mg twice daily (BID), Psyllium has been associated with anaphylactic • morphine sulfate ER orally 30 mg BID, reactions, as well (Ho et al., 2008). The palliative • morphine sulfate IR orally 10 mg every 2 to 3 care patient, generally, cannot tolerate or intake hours as needed for breakthrough pain, and the amount of fluid needed for bulk-forming laxa- • docusate sodium orally 200 mg BID. tives to work properly and safely. Background Emollients The goal of patient management for home health- Commonly known as stool softeners, these agents care providers, in particular for palliative care work by increased wetting and softening fecal patients, is the improvement of quality of life mass, which allows for easier passage of stool. issues that affect the physical and psychological Softening of stools generally occurs in 1 to 3 days well-being of their patients. These issues may in- (Powell & Fleming, 2011). Docusate is the most clude pain, fatigue, reduced mobility, and, com- commonly used stool softener and should be used monly, constipation. Constipation continues to to prevent painful defecation and straining in situ- challenge home healthcare providers, especially ations when this should be avoided such as se- in palliative care. For a detailed definition of con- vere hypertension, cardiovascular disease, and stipation, please refer to Part 1 of this article recent surgery or myocardial infarction. Docusate (Fritz & Pitlick, 2012). In an effort to improve may increase fecal soiling, otherwise there are symptoms of constipation, pharmacologic mea- very few side effects associated with these agents sures may be necessary. This second part article (Powell & Fleming, 2011). Stool softeners are 208 Home Healthcare Nurse www.homehealthcarenurseonline.com Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. ineffective in treating constipation and should not an abundance of evidence showing efficacy and be used as monotherapy for treatment of constipa- safety with PEG over placebo (Locke, et al., 2000; tion (Gallegos-Orozco et al., 2012). However, they Powell & Fleming, 2011; Ramkumar & Rao, 2005; work well when combined with stimulant laxa- Weitzel & Goode, 2012). Unlike other laxatives, tives and lead to a softer, easier stool to pass as PEG has been shown safe when used up to 6 to the stimulant causes laxation (Locke et al., 2000; 12 months (Powell & Fleming, 2011; Singh & Rao, Powell & Fleming, 2011; Weitzel & Goode, 2012). 2010). PEG has been shown superior to lactulose as well (Ramkumar & Rao, 2005). Lubricant Lactulose and sorbitol are hyperosmotic laxa- Mineral oil can soften stool and prevent strain- tives that work in a similar way. In addition to ing, similar to emollients. It typically works in 2 altering fluid activity, these agents decrease pH in to 3 days. However, safety concerns severely the colon, which increases colonic peristalsis. limit its use. Lipid pneumonia can result from This increases stool frequency and consistency. aspiration, especially in the very ill and elderly. Adverse effects include flatulence, nausea, In addition, absorption of Vitamins A, D, E, and K abdominal discomfort or bloating, diarrhea, and can be disrupted. Other adverse effects such as electrolyte imbalances. Lactulose has been shown pruritus and soiling can occur as well (Leung et to be superior to placebo for chronic constipa- al., 2011; Powell & Fleming, 2011). Given these tion and effective in opioid-induced constipation issues, mineral oil should not be recommended in (Liu, 2011). Sorbitol is similar to lactulose, is more palliative care situations (Locke et al., 2000; cost-effective, and causes less nausea. However, Powell & Fleming, 2011; Weitzel & Goode, 2012). hyperglycemia may occur with sorbitol, so it is important to monitor patients with diabetes. Osmotic Laxatives Lactulose and sorbitol could be useful in palliative These agents include glycerin, polyethylene glycol care situations; however, there are not enough stud- (PEG, brand name: Miralax), lactulose, sorbitol, ies in this patient population and more frequent use and saline laxatives such as magnesium hydrox- of the laxative is needed. See Box 1 for evidence- ide, citrate, phosphate, and sodium phosphate. based practice regarding lactulose and PEG. These agents draw water into the colon through Saline laxatives include magnesium hydrox- osmosis, leading to a softer stool, and induce a ide, citrate, sulfate, phosphate, and sodium phos- bowel movement. Adverse effects are common phates. These agents act primarily by osmosis in among these laxatives (except glycerin and PEG) the small and large intestines (oral) or colon and elderly patients tend to be more susceptible. (rectal). They increase the intraluminal pressure Glycerin is a very safe and effective laxative for acute evacuation. It is available in suppository form and induces bowel movement in 30 minutes. Box 1. Evidence-Based Practice: Adverse effects are rare but may include mild Lactulose Versus Polyethylene Glycol rectal irritation. Lactulose versus polyethylene glycol for chronic PEG is an osmotic laxative with adequate effi- constipation (Lee-Robichaud et al., 2010). cacy and a favorable adverse effect profile. PEG Research Problem: To determine if lactulose possesses fewer adverse effects than other os- or polyethylene glycol is more effective to treat motic laxatives because it is not absorbed sys- chronic constipation. temically or metabolized by colonic bacteria. For Methods: Comprehensive literature review with constipation during palliative care, PEG is an ex- meta-analysis of randomized controlled trials cellent choice because of its wetting and stimula- comparing lactulose to polyethylene glycol. tion effects with low incidence of adverse effects. Results: Ten randomized controlled trials were in- Possible adverse effects include abdominal pain, cluded. Polyethylene glycol was found to be better than lactulose in outcomes of stool frequency and electrolyte disturbances, and dehydration; how- form of stool. ever, incidence is lower than that for other laxa- Implications for home healthcare practice: tives (Clemens & Klaschik, 2008). Additionally, Polyethylene glycol should be considered over PEG must be dissolved in a glass of water (8 oz), lactulose for treatment of chronic constipation. which can be an issue if the patient is fluid re- SORT LEVEL: B stricted or cannot tolerate excess fluids. There is vol. 31 • no. 4 • April 2013 Home Healthcare Nurse 209 Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. less effective drug (Locke et al., 2000; Powell & A very common Fleming, 2011; Weitzel & Goode, 2012). In the past, clinicians have hesitated
Load more

Recommended publications
  • Effect of Single Dose Resin-Cathartic Therapy on Serum Potassium Concentration in Patients with End-Stage Renal Disease
    J Am Soc Nephrol 9: 1924-1930. 1998 Effect of Single Dose Resin-Cathartic Therapy on Serum Potassium Concentration in Patients with End-Stage Renal Disease CHRISTINE GRUY-KAPRAL, MICHAEL EMMETT, CAROL A. SANTA ANA, JACK L. PORTER, JOHN S. FORDTRAN, and KENNETH D. FINE Departnzent of Internal Medicine, Baylor Universirs’ Medical Center, Dallas, Texas. Abstract. Hyperkalemia in patients with renal failure is fre- slightly (0.4 mEqIL) during the I 2-h experiment. This rise was quently treated with a cation exchange resin (sodium polysty- apparently abrogated by some of the regimens that included rene sulfonate, hereafter referred to as resin) in combination resin; this may have been due in part to extracellular volume with a cathartic, but the effect of such therapy on serum expansion caused by absorption of sodium released from resin. potassium concentration has not been established. This study Phenolphthalein regimens were associated with a slight rise in evaluates the effect of four single-dose resin-cathartic regimens serum potassium concentrations (similar to placebo); this may and placebo on 5 different test days in six patients with chronic have been due to extracellular volume contraction produced by renal failure. Dietary intake was controlled. Fecal potassium high volume and sodium-rich diarrhea and acidosis secondary output and serum potassium concentration were measured for to bicarbonate losses. None of the regimens reduced serum 12 h. Phenobphthalein alone caused an average fecal potassium potassium concentrations, compared with baseline levels. Be- output of 54 mEq. The addition of resin caused an increase in cause single-dose resin-cathartic therapy produces no or only insoluble potassium output but a decrease in soluble potassium trivial reductions in serum potassium concentration, and be- output; therefore, there was no significant effect of resin on cause this therapy is unpleasant and occasionally is associated total potassium output.
    [Show full text]
  • 3.2.2 Misuse of Stimulant Laxatives
    Medicines Adverse Reactions Committee Meeting date 10/06/2021 Agenda item 3.2.2 Title Misuse of stimulant laxatives Submitted by Medsafe Pharmacovigilance Paper type For advice Team Active ingredient Product name Sponsor Bisacodyl Bisacodyl Laxative (Pharmacy Health) PSM Healthcare Limited trading as API tablet Consumer Brands Dulcolax tablet Sanofi-Aventis New Zealand Limited Dulcolax Suppository Sanofi-Aventis New Zealand Limited *Lax-Suppositories Bisacodyl AFT Pharmaceuticals Limited *Lax-Tab tablet AFT Pharmaceuticals Limited Docusate sodium *Coloxyl tablet Pharmacy Retailing (New Zealand) Limited trading as Healthcare Logistics Docusate sodium + Coloxyl with Senna tablet Pharmacy Retailing (New Zealand) sennosides Limited trading as Healthcare Logistics *Laxsol tablet Pharmacy Retailing (New Zealand) Limited trading as Healthcare Logistics Glycerol *Glycerol Suppositories PSM Healthcare Limited trading as API Consumer Brands Sennosides *Senokot tablet Reckitt Benckiser (New Zealand) Limited Sodium picosulfate Dulcolax SP Drops oral solution Sanofi-Aventis New Zealand Limited PHARMAC funding *Pharmaceutical Schedule Lax-Tab tablets, Lax-Suppositories Bisacodyl, Coloxyl tablets and Glycerol Suppositories are fully-funded only on a prescription. Senokot tablets are part- funded. Previous MARC Misuse of stimulant laxatives has not been discussed previously. meetings International action Following a national safety review published in August 2020, the MHRA in the UK has introduced pack size restrictions, revised recommended ages for use
    [Show full text]
  • Assessment Report on Ricinus Communis L., Oleum Final
    2 February 2016 EMA/HMPC/572973/2014 Committee on Herbal Medicinal Products (HMPC) Assessment report on Ricinus communis L., oleum Final Based on Article 10a of Directive 2001/83/EC as amended (well-established use) Herbal substance(s) (binomial scientific name Ricinus communis L., oleum (castor oil) of the plant, including plant part) Herbal preparation Fatty oil obtained from seeds of Ricinus communis L. by cold expression Pharmaceutical forms Herbal preparation in liquid or solid dosage forms for oral use Rapporteur C. Purdel Peer-reviewer B. Kroes 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ................................................................................................................... 2 1. Introduction ....................................................................................................................... 4 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4 1.2. Search and assessment methodology ..................................................................... 6 2. Data on medicinal use ........................................................................................................ 6 2.1. Information about products on the market .............................................................
    [Show full text]
  • Chronic Constipation: an Evidence-Based Review
    J Am Board Fam Med: first published as 10.3122/jabfm.2011.04.100272 on 7 July 2011. Downloaded from CLINICAL REVIEW Chronic Constipation: An Evidence-Based Review Lawrence Leung, MBBChir, FRACGP, FRCGP, Taylor Riutta, MD, Jyoti Kotecha, MPA, MRSC, and Walter Rosser MD, MRCGP, FCFP Background: Chronic constipation is a common condition seen in family practice among the elderly and women. There is no consensus regarding its exact definition, and it may be interpreted differently by physicians and patients. Physicians prescribe various treatments, and patients often adopt different over-the-counter remedies. Chronic constipation is either caused by slow colonic transit or pelvic floor dysfunction, and treatment differs accordingly. Methods: To update our knowledge of chronic constipation and its etiology and best-evidence treat- ment, information was synthesized from articles published in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Levels of evidence and recommendations were made according to the Strength of Recommendation taxonomy. Results: The standard advice of increasing dietary fibers, fluids, and exercise for relieving chronic constipation will only benefit patients with true deficiency. Biofeedback works best for constipation caused by pelvic floor dysfunction. Pharmacological agents increase bulk or water content in the bowel lumen or aim to stimulate bowel movements. Novel classes of compounds have emerged for treating chronic constipation, with promising clinical trial data. Finally, the link between senna abuse and colon cancer remains unsupported. Conclusions: Chronic constipation should be managed according to its etiology and guided by the best evidence-based treatment.(J Am Board Fam Med 2011;24:436–451.) copyright. Keywords: Chronic Constipation, Clinical Review, Evidence-Based Medicine, Family Medicine, Gastrointestinal Problems, Systematic Review The word “constipation” has varied meanings for was established in 1991 by Drossman et al, primar- different individuals.
    [Show full text]
  • Comparison of Two Cathartic Preparations, Peg-Electrolytes Solution and Sodium Phosphate Salts, As Means for Large Bowel Preparation for Colonoscopy
    276 ANNALS OF GASTROENTEROLOGY 2004,C. FOTIADIS, 17(3):276-279 et al Original article Comparison of two cathartic preparations, peg-electrolytes solution and sodium phosphate salts, as means for large bowel preparation for colonoscopy N. Antonakopoulos, I. Kyrlagkitsis, V. Xourgias, D.G. Karamanolis SUMMARY period of preparation, less inconvenience for the patient and better bowel cleansing. Twenty years ago, the whole The ideal bowel preparation for colonoscopy must combine procedure required a three-day low-residue diet, a the characteristics of effectiveness with the least side effects. laxative (bisacodyl) two days before the examination, a We compared the relatively novel cathartic preparation of cathartic preparation the previous day and an enema on R sodium phosphate salts (Fleet Phospho-soda ) with the the day of the examination.1 Today a single-day prepa- R widely used PEG-electrolytes solution (Klean-prep ). Fifty- ration with an oral cathartic solution is adequate. two consecutive patients referred for colonoscopy were randomised to receive either sodium phospate salts or PEG The aim of the present study was to compare the novel electrolytes. The evaluation of the two preparations was cathartic preparation of sodium phosphate salts (Fleet R based on two separate questionnaires, one completed by the Phospho-soda ), to the widely used PEG-electrolytes R endoscopist who ignored the kind of bowel preparation used solution (Klean-prep ), in terms of efficacy and tolerance and the other by the patient. Bowel preparation with sodium by the patient. phospate salts was more effective in bowel cleansing and better tolerated than PEG-electrolytes solution in terms of MATERIALS AND METHODS difficulty in intake and swallowing, fatigue, the presence of colicky abdominal pain, flatulence, vomiting and perianal We included all outpatients who underwent colono- irritation (p<0,05).
    [Show full text]
  • DEXEDRINE® (Dextroamphetamine Sulfate) SPANSULE® Sustained-Release Capsules and Tablets
    DX:L58 PRESCRIBING INFORMATION DEXEDRINE® (dextroamphetamine sulfate) SPANSULE® sustained-release capsules and Tablets WARNING AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY. MISUSE OF AMPHETAMINES MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS. DESCRIPTION DEXEDRINE (dextroamphetamine sulfate) is the dextro isomer of the compound d,l-amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is d-alpha-methylphenethylamine, and is present in all forms of DEXEDRINE as the neutral sulfate. Structural formula: SPANSULE capsules: Each SPANSULE sustained-release capsule is so prepared that an initial dose is released promptly and the remaining medication is released gradually over a prolonged period. Each capsule, with brown cap and clear body, contains dextroamphetamine sulfate. The 5-mg capsule is imprinted 5 mg and 3512 on the brown cap and is imprinted 5 mg and SB on the clear body. The 10-mg capsule is imprinted 10 mg—3513—on the brown cap and is imprinted 10 mg—SB—on the clear body. The 15-mg capsule is imprinted 15 mg and 3514 on the brown cap and is imprinted 15 mg and SB on the clear body. A narrow bar appears above and below 15 mg and 3514. Product reformulation in 1996 has caused a minor change in the color of the time-released pellets within each capsule.
    [Show full text]
  • Getting the Most from the Universal Antidote
    Getting the Most from the Universal Antidote Activated charcoal has been called the most as antibiotics, vitamins or amino acids. Antibiotic important “universal antidote” in the treatment of therapy should be administered parenterally intoxification by chemical agents. The term when activated charcoal is used. Fluids to antidote may be misleading since activated correct acid/base, hydration and electrolyte charcoal does not directly counteract the effects imbalances should be administered. of a poison and may not be effective with some toxicants such as heavy metals. However, finely Emesis ground activated charcoal is useful in the treatment of many poisons in animals and If an oral emetic such as syrup of ipecac, humans. hydrogen peroxide or apomorphine hydrochloride is used, activated charcoal should Activated charcoal is an amophorous form of not be administered until after emesis (vomiting). carbon in that it has no regular atomic structure Emesis is most productive if performed within 2- and differs from common charcoal that contains 3 hours post ingestion. Feeding the animal a other organic residues. Charcoal is obtained by small moist meal before inducing vomiting can burning carbon-containing materials. Charcoal increase the chances of an adequate emesis. becomes activated by heating it to extremely Emetics generally empty 40-60% of the stomach high temperatures in the absence of oxygen contents. thereby removing the residual non-carbon elements and producing a porous internal Emesis is contraindicated with ingestion of microstructure having an extremely high surface alkalis, acids, corrosive agents or hydrocarbons area. A single gram of activated charcoal USP due to the risk of chemical burns or aspiration.
    [Show full text]
  • Saline Cathartics
    Saline Cathartics Saline cathartics or purgatives are agents that quicken and increase evacuation from the bowl. Laxatives are mild cathartics. Cathartics are used: to ease defecation in patients with painful hemorrhoids or other rectal disorders and to avoid excessive straining and concurrent increase in abdominal pressure in patients with hernias Or to avoid potentially hazardous rise in B.P. during defecation in patients with hypertension, cerebral coronary or other arterial disease Or to relieve acute constipation Or to remove solid material from intestinal tract prior to certain roentgenographic studies. Laxative should only be used for short term therapy as prolonged use may lead to loss of spontaneous bowl rhythm upon which normal evacuation depends, causing patient to become dependent on laxatives, the so called laxative effect. Constipation is the infrequent or difficult evacuation of the feces. It may be due to a person resisting the natural urge to defecate, causing the fecal material which remains in the colon to lose fluid and to become relatively dry and hard. Constipation can also be due to intestinal atony, intestinal spasm, emotions, drugs and diet. Many a time constipation can be helped by eating food such as natural laxatives or food with large roughages. Four types of laxatives are known: 1. Stimulants 2. Bulk forming 3. Emollient 4. Saline cathartics Stimulants act by local irritation on the intestinal tract which increase peristaltic activity. They include phenolphthalein, aloin, cascara extract, rhubarb extract, senna extract, podophyllin, castor oil, bisacodyl, calomel etc. Bulk forming laxatives are made from cellulose, sodium carboxyl methyl cellulose and karaya gum.
    [Show full text]
  • A Consensus Document on Bowel Preparation Before Colonoscopy
    Consensus Statement A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force From The American Society of Colon and Rectal Surgeons (ASCRS), The American Society for Gastrointestinal Endoscopy (ASGE), and The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Steven D. Wexner, M.D., Task Force Chair,1 David E. Beck, M.D.2 (ASCRS), Todd H. Baron, M.D.3 (ASGE), Robert D. Fanelli, M.D.4 (SAGES), Neil Hyman, M.D.5 (ASCRS), Bo Shen, M.D.6 (ASGE), Kevin E. Wasco, M.D.7 (SAGES) 1 Department of Colorectal Surgery, Cleveland Clinic Florida, Weston, Florida 2 Department of Colon and Rectal Surgery, Ochsner Clinic Foundation, New Orleans, Louisiana 3 Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 4 Surgical Specialists of Western New England, PC/Department of Surgery, Berkshire Medical Center, Pittsfield, Massachusetts 5 Department of Surgery, University of Vermont College of Medicine, Burlington, Vermont 6 Department of Gastroenterology/Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio 7 Surgical Associates of Neenah, S.C., Neenah, Wisconsin This document appears simultaneously in the June 2006 issues of Diseases of the Colon & Rectum, Surgical Endoscopy, and Gastro- intestinal Endoscopy. This document was reviewed and approved by the SAGES Board of Governors, the ASCRS Standards Committee and Executive Council, and the ASGE Governing Board. Addendum provides manufacturers’ information for all products discussed in this document. Correspondence to: Steven D. Wexner, M.D., Department of Colorectal Surgery, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd., Weston, Florida 33331, e-mail: [email protected] Dis Colon Rectum 2006; 49: 792–809 DOI: 10.1007/s10350-006-0536-z * The American Society of Colon and Rectal Surgeons Published online: 02 May 2006 792 Vol.
    [Show full text]
  • LARISSA LUCENA PÉRICO AVALIAÇÃO DOS MECANISMOS DE AÇÃO ENVOLVIDOS NA ATIVIDADE ANTIULCEROGÊNICA DE Serjania Marginata Casa
    UNIVERSIDADE ESTADUAL PAULISTA “Júlio de Mesquita Filho” INSTITUTO DE BIOCIÊNCIAS DE BOTUCATU LARISSA LUCENA PÉRICO AVALIAÇÃO DOS MECANISMOS DE AÇÃO ENVOLVIDOS NA ATIVIDADE ANTIULCEROGÊNICA DE Serjania marginata Casar. FRENTE À DOENÇA ULCEROSA PÉPTICA EXPERIMENTAL Botucatu – SP 2014 UNIVERSIDADE ESTADUAL PAULISTA “Júlio de Mesquita Filho” INSTITUTO DE BIOCIÊNCIAS DE BOTUCATU LARISSA LUCENA PÉRICO AVALIAÇÃO DOS MECANISMOS DE AÇÃO ENVOLVIDOS NA ATIVIDADE ANTIULCEROGÊNICA DE Serjania marginata FRENTE À DOENÇA ULCEROSA PÉPTICA EXPERIMENTAL ORIENTADORA: PROF. ADJA. CLÉLIA AKIKO HIRUMA LIMA COORIENTADORA: PROFA. DRA. LÚCIA REGINA MACHADO DA ROCHA Dissertação apresentada ao Departamento de Farmacologia do Instituto de Biociências de Botucatu UNESP, como requisito para a obtenção do título de Mestre em Ciências Biológicas (área de concentração: Farmacologia). Botucatu – SP 2014 BANCA EXAMINADORA __________________________________________ 1º. Titular/ Presidente Profa Adja. Clélia Akiko Hiruma-Lima (UNESP/Botucatu) __________________________________________ 2º. Titular Profa Dra Alessandra Gambero (Universidade São Francisco/Bragança Paulista) __________________________________________ 3º. Titular Profa Dra Patricia Fidelis de Oliveira Gregolini (UNESP/Botucatu) Auxílio Financeiro: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) BIOTA- FAPESP/SP AGRADECIMENTOS Agradeço primeiramente a Deus por permitir que tudo pudesse ser realizado. Agradeço à minha família que sempre me apoiou nos momentos difíceis e compartilhou minhas alegrias. Aos meus pais, Luzia e Vanderlei, que são exemplos de ética e profissionalismo e que sempre me incentivaram nesta busca ao conhecimento e ao crescimento profissional, sempre com muito amor e carinho. Ao meu irmão, Rafael, pelo apoio, amor, carinho e compreensão. Agradeço a Deus pela família que tenho. A Tainara B. Ferrari que sempre esteve comigo me apoiando e me aconselhando. Ela me abraçou nos dias de choro e também sorriu comigo nos momentos de alegria.
    [Show full text]
  • DEXEDRINE® (Dextroamphetamine Sulfate) SPANSULE® Sustained Release Capsules CII Rx Only
    DEXEDRINE® (dextroamphetamine sulfate) SPANSULE® sustained release capsules CII Rx Only WARNING: AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY. MISUSE OF AMPHETAMINES MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS. DESCRIPTION: DEXEDRINE (dextroamphetamine sulfate) is the dextro isomer of the compound d,l-amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is d-alpha-methylphenethylamine, and is present in all forms of DEXEDRINE as the neutral sulfate. Structural formula: SPANSULE capsules: Each SPANSULE sustained-release capsule is so prepared that an initial dose is released promptly and the remaining medication is released gradually over a prolonged period. Each capsule, with brown cap and natural body, contains dextroamphetamine sulfate. The 5-mg capsule is imprinted in white with IX and 5 mg on the brown cap and is imprinted in white with 673 and 5 mg on the natural body. The 10-mg capsule is imprinted in white with IX and 10 mg on the brown cap and is imprinted in white with 674 and 10 mg on the natural body. The 15-mg capsule is imprinted in white with IX and 15 mg on the brown cap and is imprinted in white with 675 and 15 mg on the natural body. Product reformulation in 1996 has caused a minor change in the color of the time-released pellets within each capsule.
    [Show full text]
  • Mineral Oil, General Entry
    ENVIRONMENTAL CONTAMINANTS ENCYCLOPEDIA MINERAL OIL, GENERAL ENTRY July 1, 1997 COMPILERS/EDITORS: ROY J. IRWIN, NATIONAL PARK SERVICE WITH ASSISTANCE FROM COLORADO STATE UNIVERSITY STUDENT ASSISTANT CONTAMINANTS SPECIALISTS: MARK VAN MOUWERIK LYNETTE STEVENS MARION DUBLER SEESE WENDY BASHAM NATIONAL PARK SERVICE WATER RESOURCES DIVISIONS, WATER OPERATIONS BRANCH 1201 Oakridge Drive, Suite 250 FORT COLLINS, COLORADO 80525 WARNING/DISCLAIMERS: Where specific products, books, or laboratories are mentioned, no official U.S. government endorsement is intended or implied. Digital format users: No software was independently developed for this project. Technical questions related to software should be directed to the manufacturer of whatever software is being used to read the files. Adobe Acrobat PDF files are supplied to allow use of this product with a wide variety of software, hardware, and operating systems (DOS, Windows, MAC, and UNIX). This document was put together by human beings, mostly by compiling or summarizing what other human beings have written. Therefore, it most likely contains some mistakes and/or potential misinterpretations and should be used primarily as a way to search quickly for basic information and information sources. It should not be viewed as an exhaustive, "last-word" source for critical applications (such as those requiring legally defensible information). For critical applications (such as litigation applications), it is best to use this document to find sources, and then to obtain the original documents and/or talk to the authors before depending too heavily on a particular piece of information. Like a library or many large databases (such as EPA's national STORET water quality database), this document contains information of variable quality from very diverse sources.
    [Show full text]